MXSGD alleviates CsA-induced hypoimmunity lung injury by regulating microflora metabolism.
Front Immunol
; 14: 1298416, 2023.
Article
in En
| MEDLINE
| ID: mdl-38259457
ABSTRACT
Context Ma Xing Shi Gan Decoction (MXSGD) is a traditional remedy for treating lung injuries that was developed by the Typhoid and Fever School of Pharmaceutical Biology. It has antitussive and expectorant effects, anti-inflammatory, antiviral, regulates the body's immunity, etc. Aim:
The aim of this study is to investigate whether MXSGD can ameliorate cyclosporine A (CsA)-induced hypoimmunity lung injury by regulating microflora metabolism.Methods:
Establishment of a model for CsA-induced hypoimmunity lung injury. Using 16S rRNA high-throughput sequencing and LC-MS, the effects of MXSGD on gut flora and lung tissue microecology of mice with CsA-induced hypoimmunity were investigated.Results:
MXSGD was able to preserve lung tissue morphology and structure, reduce serum inflammatory marker expression and protect against CsA-induced lung tissue damage. Compared to the model, MXSGD increased beneficial gut bacteria Eubacterium ventriosum group and Eubacterium nodatum group; decreased intestinal pathogens Rikenellaceae RC9 intestinal group; reduced the abundance of Chryseobacterium and Acinetobacter, promoted the production of Lactobacillus and Streptococcus, and then promoted the lung flora to produce short-chain fatty acids. MXSGD was able to enhance the expression of serum metabolites such as Americine, 2-hydroxyhexadecanoylcarnitine, Emetine, All-trans-decaprenyl diphosphate, Biliverdin-IX-alpha, Hordatin A and N-demethyl mifepristone in the CsA-induced hypoimmunity lung injury model.Conclusion:
MXSGD can restore gut and lung microbiota diversity and serum metabolite changes to inhibit inflammation, ameliorate CsA-induced hypoimmunity lung injury.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Acinetobacter
/
Drugs, Chinese Herbal
/
Lung Injury
/
Immunologic Deficiency Syndromes
Limits:
Animals
Language:
En
Journal:
Front Immunol
Year:
2023
Document type:
Article